10 results on '"Maribavir"'
Search Results
2. Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
- Author
-
Papanicolaou, Genovefa A, Avery, Robin K, Cordonnier, Catherine, Duarte, Rafael F, Haider, Shariq, Maertens, Johan, Peggs, Karl S, Solano, Carlos, Young, Jo-Anne H, Fournier, Martha, Murray, Rose Ann, Wu, Jingyang, Winston, Drew J, and Investigators, AURORA Trial
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *PROTEIN kinase inhibitors , *DRUG toxicity , *PATIENT safety , *DRUG side effects , *RESEARCH funding , *CYTOMEGALOVIRUS diseases , *STATISTICAL sampling , *BLIND experiment , *TERMINATION of treatment , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *SURGICAL complications , *VALGANCICLOVIR , *DRUG efficacy , *RESEARCH , *VIREMIA , *CONFIDENCE intervals , *PATIENT aftercare , *NEUTROPENIA - Abstract
Background Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy of maribavir with fewer treatment-limiting toxicities than valganciclovir. Methods In this multicenter, double-blind, phase 3 study, patients with first asymptomatic CMV infection post-HCT were stratified and randomized 1:1 to maribavir 400 mg twice daily or valganciclovir (dose-adjusted for renal clearance) for 8 weeks with 12 weeks of follow-up. The primary endpoint was confirmed CMV viremia clearance at week 8 (primary hypothesis of noninferiority margin of 7.0%). The key secondary endpoint was a composite of the primary endpoint with no findings of CMV tissue-invasive disease at week 8 through week 16. Treatment-emergent adverse events (TEAEs) were assessed. Results Among patients treated (273 maribavir; 274 valganciclovir), the primary endpoint of noninferiority of maribavir was not met (maribavir, 69.6%; valganciclovir, 77.4%; adjusted difference: −7.7%; 95% confidence interval [CI]: −14.98, −.36; lower limit of 95% CI of treatment difference exceeded −7.0%). At week 16, 52.7% and 48.5% of patients treated (maribavir and valganciclovir, respectively) maintained CMV viremia clearance without tissue-invasive disease (adjusted difference: 4.4%; 95% CI: −3.91, 12.76). With maribavir (vs valganciclovir), fewer patients experienced neutropenia (16.1% and 52.9%) or discontinued due to TEAEs (27.8% and 41.2%). Discontinuations were mostly due to neutropenia (maribavir, 4.0%; valganciclovir, 17.5%). Conclusions Although noninferiority of maribavir to valganciclovir for the primary endpoint was not achieved based on the prespecified noninferiority margin, maribavir demonstrated comparable CMV viremia clearance during post-treatment follow-up, with fewer discontinuations due to neutropenia. Clinical Trials Registration. NCT02927067 [AURORA]. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
- Author
-
Chou, Sunwen, Alain, Sophie, Cervera, Carlos, Chemaly, Roy F, Kotton, Camille N, Lundgren, Jens, Papanicolaou, Genovefa A, Pereira, Marcus R, Wu, Jingyang J, Murray, Rose Ann, Buss, Neil E, and Fournier, Martha
- Subjects
- *
CLINICAL trials , *DRUG resistance , *CYTOMEGALOVIRUS diseases , *CLINICAL trial registries , *VIRAL genes - Abstract
Background This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where 56% and 24%, respectively, cleared cytomegalovirus DNA at week 8 (treatment responders). Methods Baseline and posttreatment plasma samples were tested for mutations conferring drug resistance in viral genes UL97 , UL54, and UL27. Results At baseline, genotypic testing revealed resistance to ganciclovir, foscarnet, or cidofovir in 56% of patients receiving maribavir and 68% receiving IAT, including 9 newly phenotyped mutations. Among them, 63% (maribavir) and 21% (IAT) were treatment responders. Detected baseline maribavir resistance mutations were UL27 L193F (n = 1) and UL97 F342Y (n = 3). Posttreatment, emergent maribavir resistance mutations were detected in 60 (26%) of those randomized to maribavir, including 49 (48%) of 103 nonresponders and 25 (86%) of the 29 nonresponders where viral DNA initially cleared then rebounded while on maribavir. The most common maribavir resistance mutations were UL97 T409M (n = 34), H411Y (n = 26), and C480F (n = 21), first detected 26 to 130 (median 56) days after starting maribavir. Conclusions Baseline maribavir resistance was rare. Drug resistance to standard cytomegalovirus antivirals did not preclude treatment response to maribavir. Rebound in plasma cytomegalovirus DNA while on maribavir strongly suggests emerging drug resistance. Clinical Trials Registration NCT02931539. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
- Author
-
Deray, Kristen G Valencia, Danziger-Isakov, Lara A, and Downes, Kevin J
- Subjects
- *
CYTOMEGALOVIRUS disease prevention , *HEMATOPOIETIC stem cell transplantation , *MORTALITY , *HETEROCYCLIC compounds , *PATIENTS , *TRANSPLANTATION of organs, tissues, etc. , *CYTOMEGALOVIRUS diseases , *INVESTIGATIONAL drugs , *ANTIVIRAL agents , *DRUG approval , *DISEASES , *CHILDREN - Abstract
Despite current prophylaxis regimens, cytomegalovirus (CMV) is common in hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) and remains a significant cause of morbidity and mortality. Newer antiviral medications are reshaping the landscape for prevention and treatment of CMV DNAemia, infection, and disease. Letermovir is approved for CMV prevention in adult HCT patients and is attractive due to the absence of marrow suppression seen with ganciclovir/valganciclovir. Letermovir should not be routinely used for CMV treatment due to its low threshold for resistance. Maribavir is approved for the treatment of refractory or resistant CMV disease in HCT and SOT recipients ≥12 years of age, though it has no current role in CMV prevention. More research is needed to fully elucidate the roles, efficacy, and safety of these newer agents in prevention and treatment of CMV in pediatric transplant recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Absence of maribavir penetration into the central nervous system: confirmation by multiple cerebrospinal fluid dosages in a solid organ transplant recipient.
- Author
-
Luque-Paz, David, Lalanne, Sébastien, Besombes, Juliette, Dorel, Marie, Maamar, Adel, and Revest, Matthieu
- Subjects
- *
CENTRAL nervous system , *CEREBROSPINAL fluid , *TRANSPLANTATION of organs, tissues, etc. , *KIDNEYS , *CEREBROSPINAL fluid examination , *THERAPEUTICS , *CYTOMEGALOVIRUS diseases - Abstract
This article discusses the limited penetration of the antiviral drug maribavir into the central nervous system (CNS) based on a case study of a solid organ transplant recipient with drug-resistant cytomegalovirus (CMV) infection. The patient was treated with foscarnet and maribavir, but maribavir concentrations in the cerebrospinal fluid (CSF) remained below the lower limit of quantification. Despite meningeal inflammation, which typically increases the permeability of anti-infective therapies in the CSF, maribavir failed to treat and prevent the development of CMV disseminated disease. The study suggests that maribavir should not be used for the treatment of CMV meningitis and/or encephalitis, and more data are needed to confirm its poor diffusion into the CNS. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
6. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
- Author
-
Avery, Robin K, Alain, Sophie, Alexander, Barbara D, Blumberg, Emily A, Chemaly, Roy F, Cordonnier, Catherine, Duarte, Rafael F, Florescu, Diana F, Kamar, Nassim, Kumar, Deepali, Maertens, Johan, Marty, Francisco M, Papanicolaou, Genovefa A, Silveira, Fernanda P, Witzke, Oliver, Wu, Jingyang, Sundberg, Aimee K, Fournier, Martha, and Investigators, SOLSTICE Trial
- Subjects
- *
CONFIDENCE intervals , *CYTOMEGALOVIRUS diseases , *ANTIVIRAL agents , *PATIENTS , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *PRE-tests & post-tests , *COMPARATIVE studies , *DESCRIPTIVE statistics , *DRUG resistance in microorganisms , *STATISTICAL sampling , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Background Therapies for refractory cytomegalovirus infections (with or without resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase. Methods In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up. The primary endpoint was confirmed cytomegalovirus clearance at end of week 8. The key secondary endpoint was achievement of cytomegalovirus clearance and symptom control at end of week 8, maintained through week 16. Results 352 patients were randomized (235 maribavir; 117 IAT). Significantly more patients in the maribavir versus IAT group achieved the primary endpoint (55.7% vs 23.9%; adjusted difference [95% confidence interval (CI)]: 32.8% [22.80–42.74]; P < .001) and key secondary endpoint (18.7% vs 10.3%; adjusted difference [95% CI]: 9.5% [2.02–16.88]; P = .01). Rates of treatment-emergent adverse events (TEAEs) were similar between groups (maribavir, 97.4%; IAT, 91.4%). Maribavir was associated with less acute kidney injury versus foscarnet (8.5% vs 21.3%) and neutropenia versus valganciclovir/ganciclovir (9.4% vs 33.9%). Fewer patients discontinued treatment due to TEAEs with maribavir (13.2%) than IAT (31.9%). One patient per group had fatal treatment-related TEAEs. Conclusions Maribavir was superior to IAT for cytomegalovirus viremia clearance and viremia clearance plus symptom control maintained post-therapy in transplant recipients with R/R cytomegalovirus. Maribavir had fewer treatment discontinuations due to TEAEs than IAT. Clinical Trials Registration. NCT02931539 (SOLSTICE). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
- Author
-
Chou, Sunwen, Song, Kening, Wu, Jingyang, Bo, Tien, and Crumpacker, Clyde
- Subjects
- *
CYTOMEGALOVIRUSES , *GANCICLOVIR , *GENETIC mutation , *CYTOMEGALOVIRUS diseases , *ANTIVIRAL agents , *TRANSFERASES , *RESEARCH funding , *DRUG resistance in microorganisms , *PHENOTYPES , *PHARMACODYNAMICS - Abstract
Background: In separate phase 2 trials, 120 patients received maribavir for cytomegalovirus (CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for asymptomatic infection (trial 203). Overall, 172 cleared their CMV infection (CMV DNA <200 copies/mL) within 6 weeks.Methods: Baseline and posttreatment plasma samples were tested for mutations in viral genes UL97, UL54, and/or UL27. Selected viral mutants were phenotyped for drug susceptibility.Results: Baseline samples revealed UL54 mutations newly phenotyped as conferring resistance to standard DNA polymerase inhibitor(s), including K493N, P497S, K513T, L565V, V823A, A987V, and E989D. Of 29 patients (including 25 from trial 202) who cleared but later experienced recurrent CMV infection while on maribavir, 23 had available UL97 genotyping data; 17 had known resistance mutations (T409M or H411Y) and 5 additional had UL97 C480F alone. The newly phenotyped mutation C480F conferred high-grade maribavir resistance and low-grade ganciclovir resistance. Among 25 who did not respond to >14 days of therapy, 9 showed T409M or H411Y and 4 others showed C480F alone.Conclusions: After maribavir therapy (400-1200 mg twice daily), UL97 mutations T409M, H411Y, or C480F emerge to confer maribavir resistance in patients with recurrent CMV infection while on therapy or no response to therapy.Clinical Trials Registration: NCT01611974 and EudraCT 2010-024247-32. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
- Author
-
Bravo, Marta Santos, Plault, Nicolas, Palomino, Sonsoles Sánchez, Gutierrez, María Mar Mosquera, Avilés, Francesc Fernández, Lledo, María Suarez, Fernández, Nuria Sabé, Rovira, Montserrat, Alain, Sophie, Maeso, M Ángeles Marcos, Santos Bravo, Marta, Sánchez Palomino, Sonsoles, Mosquera Gutierrez, María Mar, Fernández Avilés, Francesc, Suarez Lledo, María, Sabé Fernández, Nuria, and Marcos Maeso, M Ángeles
- Subjects
- *
HEMATOPOIETIC stem cells , *TRANSPLANTATION of organs, tissues, etc. , *PHENOTYPES , *CYTOMEGALOVIRUS diseases , *GENOTYPES , *PAROXYSMAL hemoglobinuria , *CHRONIC hepatitis B , *GANCICLOVIR , *CYTOMEGALOVIRUSES , *RESEARCH , *GENETIC mutation , *HETEROCYCLIC compounds , *NUCLEOSIDES , *RESEARCH methodology , *PATIENTS , *KIDNEY transplantation , *ANTIVIRAL agents , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *TRANSFERASES , *RESEARCH funding , *DRUG resistance in microorganisms , *HEMATOPOIETIC stem cell transplantation , *PHARMACODYNAMICS - Abstract
Two transplant recipients (1 kidney and 1 hematopoietic stem cell) received maribavir (MBV) after cytomegalovirus (CMV) infection clinically resistant to standard therapy. Both patients achieved CMV DNA clearance within 30 and 18 days; however, the UL97 C480F variant emerged, causing recurrent CMV infection after a cumulative 2 months of MBV and 15 or 4 weeks of ganciclovir treatment, respectively. C480F was not detected under ganciclovir before MBV treatment. Recombinant phenotyping showed that C480F conferred the highest level of MBV resistance and ganciclovir cross-resistance, with impaired viral growth. Clinical follow-up and genotypic and phenotypic studies are essential for the assessment and optimization of patients with suspected MBV resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Advances in the Development of Therapeutics for Cytomegalovirus Infections.
- Author
-
Acosta, Edward, Bowlin, Terry, Brooks, Jennifer, Chiang, Lillian, Hussein, Islam, Kimberlin, David, Kauvar, Lawrence M, Leavitt, Randi, Prichard, Mark, and Whitley, Richard
- Subjects
- *
CYTOMEGALOVIRUS diseases , *THERAPEUTICS , *HIV infections , *HIV , *MONOCLONAL antibodies - Abstract
The development of therapeutics for cytomegalovirus (CMV) infections, while progressing, has not matched the pace of new treatments of human immunodeficiency virus (HIV) infections; nevertheless, recent developments in the treatment of CMV infections have resulted in improved human health and perhaps will encourage the development of new therapeutic approaches. First, the deployment of ganciclovir and valganciclovir for both the prevention and treatment of CMV infections and disease in transplant recipients has been further improved with the licensure of the efficacious and less toxic letermovir. Regardless, late-onset CMV disease, specifically pneumonia, remains problematic. Second, the treatment of congenital CMV infections with valganciclovir has beneficially improved both hearing and neurologic outcomes, both fundamental advances for these children. In these pediatric studies, viral load was decreased but not eliminated. Thus, an important lesson learned from studies in both populations is the need for new antiviral agents and the necessity for combination therapies as has been shown to be beneficial in the treatment of HIV infections, among others. The development of monoclonal antibodies, sirtuins, and cyclopropovir may provide new treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
- Author
-
Papanicolaou, Genovefa A, Silveira, Fernanda P, Langston, Amelia A, Pereira, Marcus R, Avery, Robin K, Uknis, Marc, Wijatyk, Anna, Wu, Jingyang, Boeckh, Michael, Marty, Francisco M, and Villano, Stephen
- Subjects
- *
ANTIVIRAL agents , *CYTOMEGALOVIRUS diseases , *DNA , *DRUG resistance , *HEMATOPOIETIC stem cell transplantation , *GENETIC mutation , *NEUTROPHILS , *NUCLEOSIDES , *TASTE disorders , *TIME , *TRANSPLANTATION of organs, tissues, etc. , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *ADVERSE health care events , *DESCRIPTIVE statistics , *THERAPEUTICS - Abstract
Background Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to available antivirals ([val]ganciclovir, foscarnet, cidofovir) are associated with higher mortality in transplant patients. Maribavir is active against RR CMV strains. Methods Hematopoietic-cell or solid-organ transplant recipients ≥12 years old with RR CMV infections and plasma CMV deoxyribonucleic acid (DNA) ≥1000 copies/mL were randomized (1:1:1) to twice-daily dose-blinded maribavir 400, 800, or 1200 mg for up to 24 weeks. The primary efficacy endpoint was the proportion of patients with confirmed undetectable plasma CMV DNA within 6 weeks of treatment. Safety analyses included the frequency and severity of treatment-emergent adverse events (TEAEs). Results From July 2012 to December 2014, 120 patients were randomized and treated (40 per dose group): 80/120 (67%) patients achieved undetectable CMV DNA within 6 weeks of treatment (95% confidence interval, 57–75%), with rates of 70%, 63%, and 68%, respectively, for maribavir 400, 800, and 1200 mg twice daily. Recurrent on-treatment CMV infections occurred in 25 patients; 13 developed mutations conferring maribavir resistance. Maribavir was discontinued due to adverse events in 41/120 (34%) patients, and 17/41 discontinued due to CMV infections. During the study, 32 (27%) patients died, 4 due to CMV disease. Dysgeusia was the most common TEAE (78/120; 65%) and led to maribavir discontinuation in 1 patient. Absolute neutrophil counts <1000/µL were noted in 12/106 (11%) evaluable patients, with rates similar across doses. Conclusions Maribavir ≥400 mg twice daily was active against RR CMV infections in transplant recipients; no new safety signals were identified. Clinical Trials Registration NCT01611974. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.